EPIRHBICIN (E) is one of a series of new anthracycline antibiotics synthesized in an attempt to identify agents with a superior therapeutic index to the parent compound doxorubicin (DX). The acute and chronic toxicity of E is less than of DX in equimolar doses. GI cancer is generally considered as a chemotherapy resistant tumour and in this disease equitoxic'doses of E compared with DX could be of interest. In locally advanced oesofageal cancer E has been combined with radiotherapy (3.400-3.800 Gy). E in a daily dose of 50 mg/m 2 days 1,2,22,23. Out of 17 evaluab~e patients 6 complete and 7 partial responses were achieve~ with a median duration of 6+ months. In advanced gastric carcinoma 5-fluorouracil (5-FU) and adria/nycin (A) have definite activity. Used as a single agent E showed a response in 4 out of 15 patients. E was given in a dose of 50 mg/m ~ day I and day 2, every 3 weeks. In a randomized trial compar• 5-FU vs. 5-FU and E, the combination showed a significantly higher response rate (41%) than 5-FU alone (20%). In this study that included 62 evaluable patients, E was given in a dose of 40 mg/m 2 day i and 2. The median duration of remission was 8 months in the combination group. In advanced pancreatic carcinoma the EORTC GI group has conducted a phase II trial using E as single drug in a dose of 90 mg/m 2 day i every 4 weeks with dose escalation. Out of 30 fully evaluable patients 8 respo~es were noted. Toxicity was slight with a median nadir of white cells of 2.7x109/L. Median duration of response was 7 months. In colorectal carcinoma the most clinical trials with E have been performed. There has emerged a difference in activity between colon and rectosigmoid carcinoma which is not clearly understood. In colorectal carcinoma 26 responses (9%) in 300 patients have been reported in compilated series. In rectosigmoid carcinoma response rate was 13%, and in previously untreated patients 24%. It is concluded that E appears to have activity in GI cancer, esp. in gastric and pancreatic cancer. Treahnent modalities for recurrent disease will soon be needed. They should be derived from the experiences of larger studies. During a 12 months period 31 institutions entered 72 patients onto a prQtocol for low-dose IFN in HCL. 3 were excluded by the histopathologic reviewers. Recruihnent increased steadily over the observed t~me 59 patients :received 2~I0 IU Hu-rIFN~-2carg(Berofor~)s.c. daily for at least 28 days. Patients entering beyond july 1984 were randmmized after 84 days of treatment, if they reached stage A or I according to Jansen either to receive maintenance or to stop therapy.
IFN will be reinstituted whenever stage A/I will be lost. Occurrence of ccr~plete remissions, total required doses to maintain A/I-stage, and emergence of antibcdies to IFN will be evaluated for both treatment arms. 20 patients entered the protocol prior to splenectomy. No complications occurred so far. 5 out of 35 splenectc~ized patients died due to deteriorating infections (4) or CNSbleeding (I). These deaths prompted us, to try further dose reduction. In 2 out of 5 2.105IU IFN worked so far, 3 patients are to0early for evaluation.
Medizinische Klinik, Klinikstraf~ 36, D-6300 GIESSI~N Hairy cell leukemia has been shown to be extraordinary sensitive to treatment with alpha-Interferon. Therefore it represents a unique model for studying the efficacy of various dose regimens. We present the results of a phase II trial with two different dose schedules of alpha IFN. Firstly a conventional dose schedule, and secondly, a biologically defined dose regimen: We tried to define clinically effective Interferon doses by assessment of a biochemical marker. Neopteris, the marker molecule chosen,is a stable GTP-degradation product, wich is produced in Macrophages. The key enzyme of this metabolic pathway, a GTP-cyclohydrolase is regulated by interferons in an dosedependent manner ( J.Exp.Med 160:310-316). Thus the neopterin level in serum and urine reflects the local interferon concentration in the tissue. Eleven patients were entered in the study. In the first group,six patients were ~re~ted with conventional doses of rhu-IFN-alpha 2 (3xlO /m /d s.c.). In the second group (5 pts) individual dose finding was performed at the beginning of IFN-ther~py IFN was administered subcutanously 5 beginning with Ixl0~U per day and then increased by ixlO q.d.s, for two weeks. In parallel neopterin excretion in the urine was assessed daily by radioimmunoassay. The minimal IFN dose wich induced maximum neopterin excretion was chose% for further treatment. IFN doses in the order of 5-7xlOJU/d proved to be sufficient for triggering maximum neopterin excretion in the urine.After one year of Interferon treatment all patients were evaluable. At this time both dose regimens proved to be effective in terms of their antileukemic activity, but differed significantly in toxicity. Side effects were only seen in patients who received "conventional" doses. Abtlg f. Klin. Immunbiologie, Univ. Klinik f. Innere Hsdizin, A-6020 Innsbruck, Anichstr. 35
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